Free Trial
NASDAQ:LENZ

LENZ Therapeutics (LENZ) Stock Price, News & Analysis

LENZ Therapeutics logo
$33.81 -0.10 (-0.29%)
(As of 11:15 AM ET)

About LENZ Therapeutics Stock (NASDAQ:LENZ)

Key Stats

Today's Range
$33.10
$34.40
50-Day Range
$20.65
$37.25
52-Week Range
$14.42
$38.93
Volume
24,124 shs
Average Volume
136,533 shs
Market Capitalization
$929.78 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$35.40
Consensus Rating
Buy

Company Overview

LENZ Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. The company is headquartered in Del Mar, California.

LENZ Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
14th Percentile Overall Score

LENZ MarketRank™: 

LENZ Therapeutics scored higher than 14% of companies evaluated by MarketBeat, and ranked 917th out of 963 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    LENZ Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.14, and is based on 6 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    LENZ Therapeutics has only been the subject of 3 research reports in the past 90 days.

  • Read more about LENZ Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for LENZ Therapeutics are expected to decrease in the coming year, from ($2.09) to ($2.54) per share.

  • Price to Book Value per Share Ratio

    LENZ Therapeutics has a P/B Ratio of 4.33. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about LENZ Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    9.22% of the float of LENZ Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LENZ Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in LENZ Therapeutics has recently increased by 2.99%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    LENZ Therapeutics does not currently pay a dividend.

  • Dividend Growth

    LENZ Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.22% of the float of LENZ Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    LENZ Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in LENZ Therapeutics has recently increased by 2.99%, indicating that investor sentiment is decreasing.
  • News Sentiment

    LENZ Therapeutics has a news sentiment score of 1.20. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.46 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for LENZ Therapeutics this week, compared to 2 articles on an average week.
  • MarketBeat Follows

    3 people have added LENZ Therapeutics to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, LENZ Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    38.40% of the stock of LENZ Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    54.32% of the stock of LENZ Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about LENZ Therapeutics' insider trading history.
Receive LENZ Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for LENZ Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

LENZ Stock News Headlines

HC Wainwright Expects Higher Earnings for LENZ Therapeutics
Trump won. Buy this coin now.
Juan Villaverde called the top and bottom of every crypto bull market since 2012. He believes Bitcoin will go to $150,000 — or more. But there’s one coin he thinks could go even higher.
William Blair Has Optimistic Outlook of LENZ FY2024 Earnings
See More Headlines

LENZ Stock Analysis - Frequently Asked Questions

LENZ Therapeutics' stock was trading at $16.20 at the start of the year. Since then, LENZ shares have increased by 109.3% and is now trading at $33.91.
View the best growth stocks for 2024 here
.

LENZ Therapeutics, Inc. (NASDAQ:LENZ) posted its quarterly earnings results on Wednesday, November, 6th. The company reported ($0.38) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.09.

LENZ Therapeutics' top institutional investors include Geode Capital Management LLC (1.23%), State Street Corp (1.05%), Parkman Healthcare Partners LLC (0.51%) and Charles Schwab Investment Management Inc. (0.45%). Insiders that own company stock include Ra Capital Management, LP and James W Mccollum.
View institutional ownership trends
.

Shares of LENZ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Based on aggregate information from My MarketBeat watchlists, some other companies that LENZ Therapeutics investors own include NVIDIA (NVDA), Meta Platforms (META), Tesla (TSLA), Advanced Micro Devices (AMD), Visa (V), JPMorgan Chase & Co. (JPM) and Netflix (NFLX).

Company Calendar

Last Earnings
11/06/2024
Today
11/21/2024
Fiscal Year End
12/31/2024
Next Earnings (Estimated)
2/05/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
N/A
Current Symbol
NASDAQ:LENZ
Previous Symbol
NASDAQ:LENZ
Fax
N/A
Employees
N/A
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$35.40
High Stock Price Target
$38.00
Low Stock Price Target
$32.00
Potential Upside/Downside
+4.4%
Consensus Rating
Buy
Rating Score (0-4)
3.14
Research Coverage
7 Analysts

Profitability

Net Income
$-124,650,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$7.83 per share

Miscellaneous

Free Float
16,941,000
Market Cap
$932.53 million
Optionable
N/A
Beta
0.36
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:LENZ) was last updated on 11/21/2024 by MarketBeat.com Staff
From Our Partners